CHRNA5 and nicotine dependence: If these findings are tested and validated in the clinical setting, it is possible that they can be used as biomarkers to identify high-risk subgroups (e.g., carriers of the risk allele, those with hypomethylation or reduced expression of CHRNA5) or as therapeutic targets for nicotine addiction treatment.